NCT00332215View on ClinicalTrials.gov

A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

PHASE1TerminatedINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

February 28, 2006

Conditions

Cystic Fibrosis

Interventions

DRUG

Inhaled Sodium Pyruvate

Trial Locations (1)

55455

University of Minnesota General Clinical Research Center, Minneapolis

Sponsors

Collaborators (1)

Cellular Sciences, inc.

All Listed Sponsors

collaborator

Cellular Sciences, inc.

INDUSTRY

lead

University of Minnesota

OTHER

NCT00332215 - A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. | Biotech Hunter | Biotech Hunter